News

Stay up-to-date with our latest news and company announcements.

July 20, 2022

CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic

Proceeds to Support Clinical Development of Lead CNS & Liver Programs;  IND for Dravet Syndrome is Anticipated by Mid-2023  New Capital Will Also Fuel Expansion of CAMP4’s RNA Actuating Platform™, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression  Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square Capital; Enavate CEO Jim…

July 11, 2022

Enavate Sciences Appoints Industry Veteran Robert Glassman as Executive Vice President, Search & Evaluation

MENLO PARK, Calif., July 11, 2022—Enavate Sciences, a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation. In this newly created role, Dr. Glassman will report to James Boylan, Chief Executive Officer of Enavate Sciences, and will be…

June 22, 2022

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Financing from new and existing investors will support continued development of a novel treatment for food allergy Jim Momtazee and George Montgomery to join Alladapt’s Board of Directors MENLO PARK, Calif., June 22, 2022— Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of…

May 2, 2022

Patient Square Capital Announces the Formation of Enavate Sciences to Invest in and Support Therapeutic Companies

James Boylan, Accomplished Health Care Executive, Joins Enavate as CEO $300 Million Initial Investment Commitment Received MENLO PARK, Calif., May 2, 2022 – Patient Square Capital (“Patient Square”), a leading dedicated health care investment firm, today announced the formation of a new portfolio company, Enavate Sciences, to invest in and enable the growth of therapeutic…

Page 1 of 1